Description
PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS
Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS
€2.42
Related products
-
Article: INTRODUCTION
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: Calendar of events
€2.42 Add to cart -
Article: Highlights in respiratory oncology
€2.42 Add to cart
